Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/11/18 15:50:28」(JST)

wiki en

Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.^[1]^[2]^[3]

Telbivudine is a synthetic thymidine nucleoside analogue; it is the L-isomer of thymidine. It is taken once daily.

References

^ Lai CL, Leung N, Teo EK, et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology 129 (2): 528–36. doi:10.1016/j.gastro.2005.05.053. PMID 16083710.
^ Lai CL, Gane E, Liaw YF, et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med 357 (25): 2576–88. doi:10.1056/NEJMoa066422. PMID 18094378.
^ Chan HL, Heathcote EJ, Marcellin P, et al. (4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med 147 (11): 745–54. PMID 17909201. http://www.annals.org/cgi/content/full/147/11/745.

External links

Tyzeka official website run by Novartis Pharmaceuticals Corporation
Telbivudine entry in RxList
Sebivo Summary of Product Characteristics (from the EMEA website)

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 慢性B型肝炎ウイルス感染の治療におけるテルビブジン telbivudine in the treatment of chronic hepatitis b virus infection
2. B型肝炎の管理の概要および症例 overview of the management of hepatitis b and case examples
3. 慢性B型肝炎ウイルス感染に対する併用療法 combination therapy for chronic hepatitis b virus infection
4. HIV感染患者に対するB型肝炎治療のための抗ウイルス剤 antiviral medications for the treatment of hepatitis b in the hiv infected patient
5. B型肝炎ウイルス遺伝子型の臨床的意義 clinical significance of hepatitis b virus genotypes

English Journal

Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency.

Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF.SourceDepartment of Medicine, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China; State Key Laboratory for Liver Research, University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.Clin Gastroenterol Hepatol.2013 Aug;11(8):1004-1010.e1. doi: 10.1016/j.cgh.2013.01.026. Epub 2013 Feb 1.
BACKGROUND & AIMS: Few studies have investigated the effects of different nucleos(t)ide analogues against hepatitis B virus (HBV) on levels of covalently closed circular DNA (cccDNA) and hepatitis B surface antigen (HBsAg) in patients. We measured the magnitude of reduction of cccDNA and HBsAg b
PMID 23376799

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections.

Lin MT, Chou YP, Hu TH, Yu HC, Hsu YC, Tsai MC, Tseng PL, Chang KC, Yen YH, Chiu KW.SourceDivision of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, 123, Ta-Pei Road, Niao-Sung Dist., Kaohsiung, 833, Taiwan.
Archives of virology.Arch Virol.2013 Jul 16. [Epub ahead of print]
We evaluated second-line salvage therapy with adefovir + telbivudine (group 1), adefovir followed by adefovir + telbivudine (group 2), or lamivudine + adefovir followed by adefovir + telbivudine (group 3) in hepatitis B patients with an inadequate virologic response to lamivudine treatment. Simple l
PMID 23857507

Efficacy and safety of telbivudine therapy in liver failure patients with chronic hepatitis B virus infection.

Wang L, Chen H, Fan C, Gong Z.SourceDepartment of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan, China.
Journal of medical virology.J Med Virol.2013 Jul 12. doi: 10.1002/jmv.23689. [Epub ahead of print]
The objective of this study was to evaluate the short-term efficacy and safety of telbivudine therapy as compared to lamivudine therapy in liver failure patients with chronic hepatitis B virus (HBV) infection. These data were collected from 38 liver failure patients with chronic HBV infection who we
PMID 23852947

Japanese Journal

妊娠後期におけるtelbivudineまたはラミブジンの投与は周産期のB型肝炎ウイルス母子感染を安全に抑制する : 臨床実地

Hepatology : official journal of the American Association for the Study of Liver Diseases 9(3), 10-18, 2014-12
NAID 40020321307

新規抗HBV薬 (特集抗ウイルス薬) -- (新規抗ウイルス薬の開発動向と展望)

日本臨床 70(4), 660-663, 2012-04
NAID 40019238559

LIVER, PANCREAS, AND BILIARY TRACT GLOBE試験2年間の結果--B型慢性肝炎患者においてtelbivudineはラミブジンより優れている

Review of gastroenterology & clinical gastroenterology and hepatology 4(2), 56-59, 2009-08
NAID 40016795574

Related Pictures

★リンクテーブル★

リンク元

「テルビブジン」

Telbivudine
Systematic (IUPAC) name
	1-(2-deoxy-β-L-erythro-pentofuranosyl)-5-methylpyrimidine-2,4(1H,3H)-dione
Clinical data
Trade names	Tyzeka
AHFS/Drugs.com	monograph
MedlinePlus	a607045
Licence data	EMA:Link, US FDA:link
Pregnancy cat.	B (US)
Legal status	POM (UK) ℞-only (US)
Routes	Oral
Pharmacokinetic data
Protein binding	Low (3.3% in vitro)
Metabolism	Nil
Half-life	40 to 49 hours (terminal phase)
Excretion	Renal
Identifiers
CAS number	3424-98-4
ATC code	J05AF11
PubChem	CID 159269
DrugBank	DB01265
ChemSpider	140081
UNII	2OC4HKD3SF
ChEMBL	CHEMBL374731
Synonyms	1-(2-deoxy-β-L-ribofuranosyl)-5-methyluracil; β-L-2-deoxythymidine; β-L-thymidine (LdT); 1-[(2S,4R,5S)-4-hydroxy-5-hydroxymethyltetrahydrofuran-2-yl]-5-methyl-1H-pyrimidine-2,4-dione
Chemical data
Formula	C10H14N2O5
Mol. mass	242.23 g/mol
	SMILES O=C/1NC(=O)N(\C=C\1C)[C@H]2O[C@H]([C@H](O)C2)CO;
	InChI InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m1/s1 ; Key:IQFYYKKMVGJFEH-CSMHCCOUSA-N ;
(what is this?) (verify);

　　[★]

英: telbivudine
関: B型肝炎

ヌクレオシド誘導体
慢性B型肝炎治療薬

特徴

構造

作用機序

薬理作用

抗菌スペクトル

動態

適応

注意

禁忌

副作用

[Lai1-1] Lai CL, Leung N, Teo EK, et al. (2005). "A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B". Gastroenterology 129 (2): 528–36. doi:10.1016/j.gastro.2005.05.053. PMID 16083710.

[NEJM-2] Lai CL, Gane E, Liaw YF, et al. (2007). "Telbivudine versus lamivudine in patients with chronic hepatitis B". N Engl J Med 357 (25): 2576–88. doi:10.1056/NEJMoa066422. PMID 18094378.

[3] Chan HL, Heathcote EJ, Marcellin P, et al. (4 December 2007). "Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial". Ann Intern Med 147 (11): 745–54. PMID 17909201. http://www.annals.org/cgi/content/full/147/11/745.

匿名

検索

案内

案内

telbivudine